Answers are grounded in this paper and cite their sources.
Objectives: Mechanical chronic low back pain (CLBP) associated with multifidus muscle dysfunction is a major cause of disability and increased healthcare resource utilization (HRU). Existing evidence and literature have analyzed and reported the clinical value resulting from restorative neurostimulation for mechanical CLBP (e.g., reductions in pain and improvements in quality of life). This analysis adds to this literature by evaluating the economic value of restorative neurostimulation using two distinct analyses: (1) examining its potential impact on HRU and (2) estimating its cost-effectiveness based on its improvement in quality of life and potential impact on HRU. Materials and Methods: For the HRU analysis, information on HRU was collected from the RESTORE clinical trial, which randomized participants to restorative neurostimulation or optimal medical management (OMM). Back-pain-related HRU measures (e.g., medical visits, medication usage, treatments and procedures) were self-reported for the 1-year period prior to randomization (1-year baseline observations) and at 1- and 2-year follow-up for each randomized arm, and were monetized using Medicare unit costs. HRU outcomes were summarized using descriptive statistics, including total utilization counts, per-participant means, and associated costs. For the cost-effectiveness analysis, we compared the health and economic outcomes of restorative neurostimulation with those of OMM over a 5-year time horizon using a Markov cohort model. Healthcare sector and partial societal perspectives were used. The primary intervention effect associated with restorative neurostimulation was a quality-of-life improvement, but the potential impact on HRU was explored in scenario analyses. Uncertainty and variability in key model inputs were assessed through sensitivity and scenario analyses. Results: For the HRU analysis, a comparison of the year prior to baseline with the one-year randomization phase (1-year visit) showed that participants receiving restorative neurostimulation required fewer healthcare services. Interventional pain procedures decreased from a mean of 1.28 treatments per participant at baseline to 0.14 at the 1-year visit; physical rehabilitation-related treatments decreased from a mean of 17.90 to 5.15 per patient. By comparison, the control group showed smaller reductions, from a mean of 1.60 to 1.33 interventional treatments and 22.93 to 19.47 physical rehabilitation treatments per participant. Across all CPT-coded treatments, restorative neurostimulation was associated with a $1079 per-participant cost saving compared with OMM. For the cost-effectiveness analysis, the incremental cost-effectiveness ratio was around $43,000 per quality-adjusted life year gained from the healthcare sector perspective and was cost-saving from the partial societal perspective. Incorporating the potential impact on HRU resulted in more favorable cost-effectiveness estimates. Conclusions: Restorative neurostimulation may be associated with reduced HRU and is expected to be cost-effective from a healthcare sector perspective and potentially cost-saving to society. These findings support the economic value of restorative neurostimulation in appropriately selected patients with chronic low back pain associated with multifidus dysfunction. (ClinicalTrials.gov NCT04803214).
No takes yet. Share an insight, caveat, or question.
Lafage et al. (2026) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: